Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg - lozenge - excipient ingredients: magnesium stearate; sodium carbonate; sucralose; acesulfame potassium; calcium polycarbophil; potassium bicarbonate; mannitol; sodium alginate; xanthan gum; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg - lozenge - excipient ingredients: mannitol; sucralose; acesulfame potassium; potassium bicarbonate; sodium carbonate; magnesium stearate; sodium alginate; xanthan gum; calcium polycarbophil; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Malta - English - Medicines Authority

ayrton saunders (ireland) limited 8a sandyford business centre blackthorn avenue, sandyford dublin 18, , ireland - nicotine - pressurised inhalation, solution - nicotine 0.45 mg - other nervous system drugs

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine polacrilex, quantity: 20 mg (equivalent: nicotine, qty 4 mg) - lozenge - excipient ingredients: sucralose; sodium carbonate; sodium bicarbonate; mannitol; magnesium stearate; hypromellose; xanthan gum; indigo carmine aluminium lake; acesulfame potassium; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; flavour - for the relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. it may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. it should be used as part of a behavioural support programme.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 12 mg - gum, chewing - excipient ingredients: acesulfame potassium; sorbitol; sodium carbonate; butylated hydroxytoluene; menthol; sodium bicarbonate; purified talc; carnauba wax; flavour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 12 mg - gum, chewing - excipient ingredients: purified talc; butylated hydroxytoluene; acesulfame potassium; sodium bicarbonate; menthol; carnauba wax; sodium carbonate; sorbitol; flavour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 12 mg - gum, chewing - excipient ingredients: purified talc; sodium bicarbonate; butylated hydroxytoluene; sodium carbonate; sorbitol; acesulfame potassium; carnauba wax; menthol; flavour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 12 mg - gum, chewing - excipient ingredients: sodium bicarbonate; carnauba wax; acesulfame potassium; purified talc; sorbitol; butylated hydroxytoluene; sodium carbonate; menthol; flavour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 12 mg - gum, chewing - excipient ingredients: sorbitol; sodium bicarbonate; purified talc; carnauba wax; sodium carbonate; menthol; butylated hydroxytoluene; acesulfame potassium; flavour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - nicotine polacrilex, quantity: 24.44 mg - gum, chewing - excipient ingredients: carnauba wax; sodium bicarbonate; sorbitol; sodium carbonate; butylated hydroxytoluene; menthol; acesulfame potassium; purified talc; quinoline yellow aluminium lake; flavour; colour; calcium carbonate; isobutylene/isoprene copolymer; polyethylene; polyvinyl acetate; glycerol ester of gum rosin; glycerol ester of polymerised rosin; synthetic terpene resin; microcrystalline wax; hydrogenated vegetable oil; mono- and di- glycerides - treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers currently unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.